ESTRO 2024 - Abstract Book
S664
Clinical - Breast
ESTRO 2024
Intermediate (11-40%)
66
81.5
High (41-90%)
12
14.8
Unknown
0
0
3
3.7
Chemotherapy
Yes
2
2.5
No
79
97.5
Hormone therapy
Yes
76
93.8
No
5
6.2
Adherence to hormone therapy
Yes
No
61
75.3
20
24.7
Acute adverse effects
N
%
Seroma
14
17.3
Edema
3
3.7
Hematoma
3
3.7
Chronic adverse effects
N
%
Fat necrosis
4
4.9
Fibrosis
1 3
1.2 3.7
Localizad pain
Figure 1: Association between breast carcinoma subtype and stromal percentage of TILs
Made with FlippingBook - Online Brochure Maker